Droperidol: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 65: | Line 65: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:56, 20 March 2026
Administration
- Type: antipsychotic, antiemetics
- Dosage Forms: 5mg/2mL
- Routes of Administration: IV/IM
- Common Trade Names: Inapsine
Adult Dosing
Combative patient
- 5-10mg IV
- 10mg IM
Nausea/vomiting
- 0.625-2.5mg IV
Headache
- 2.5mg IV or 2.5-5mg IM
Pain (with or without opiate tolerance)
Pediatric Dosing
Nausea/vomiting
- 2-12yo: 0.015-0.1mg/kg IV/IM
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: Administer with caution
- Hepatic dosing: Administer with caution
Contraindications
- Allergy to class/drug
- Known or suspected prolonged QT
Adverse Reactions
Serious
- Prolonged QT, torsades, ventricular tachycardia, cardiac arrest
- Note: effect on QT interval is dose-dependent
- In 2001, FDA gave black box warning for risk of torsades de pointes, however there was little evidence to support this
- Large cohort of patients in ED showed safety of its administration[3]
- Neuroleptic malignant syndrome
- Anaphylaxis
Common
- Somnolence, dysphoria, anxiety
- Akathisia
- Hypotension
- Tachycardia
Pharmacology
- Half-life: 123-147m (adults), 75-127m (children)
- Metabolism: hepatic
- Excretion: mostly renal
Mechanism of Action
- Dopamine (D2) antagonist. Some serotonergic, histaminergic, and α-adrenergic effect
Comments
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Agitated or combative patient | 5 mg IM q5min x2 | 1st line antipsychotic for acute agitation | IM | Adult |
| Headache | 1.25-2.75 mg IV or IM | 2nd/3rd line for acute headache | IV/IM | Adult |
| Migraine headache | 1.25-2.75 mg IV or IM | 2nd/3rd line for acute headache | IV/IM | Adult |
See Also
External Links
- emDOCs: Droperidol Use in the Emergency Department – What’s Old is New Again
- ACEP: Oldie but a Goodie: 10 Pearls of Droperidol
References
- ↑ Richards JR, Richards IN, Ozery G, Derlet RW. Droperidol analgesia for opioid-tolerant patients. J Emerg Med. 2011 Oct;41(4):389-96. doi: 10.1016/j.jemermed.2010.07.005. Epub 2010 Sep 15. PMID: 20832967.
- ↑ Miller AC, Khan AM, Castro Bigalli AA, Sewell KA, King AR, Ghadermarzi S, Mao Y, Zehtabchi S. Neuroleptanalgesia for acute abdominal pain: a systematic review. J Pain Res. 2019;12:787-801 https://doi.org/10.2147/JPR.S187798
- ↑ Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38(7):1310-1314. doi:10.1016/j.ajem.2019.09.007